Whalesbook
Biopharma SHAKTI: Desh bane ga global hub!
Government ka yeh plan bahut bada hai, jiska goal hai India ko biomanufacturing mein world leader banana. Ye sirf generic drugs tak seemit nahi hai, balki high-value biologics aur biosimilars par focus karega. Isse India mein manufacturing badhegi, import kam hoga, aur hum global supply chains ka strong hissa banenge. Lekin jab baat aati hai company-specific performance ki, toh sabka track record aur strategy alag hai.
Syngene International: Client pressure mein transition phase
Syngene International, jo research se manufacturing tak sab kuch provide karti hai, filhaal ek transition phase se guzar rahi hai. Q3 FY26 mein ek bade customer ke biologics product mein problem aane ki wajah se revenue aur profit dono kam hue hain. Fir bhi, unka research business grow kar raha hai aur manufacturing capacity bhi better use ho rahi hai. Unhone Bristol Myers Squibb ke saath partnership ko 2035 tak extend kiya hai aur biologics scale-up ke liye advanced facilities mein invest kar rahe hain. Lekin, short term mein growth thoda slow rehne ka andaza hai. Syngene ka P/E ratio lagbhag 45.03 hai. Analysts ko revenue mein 13% annual growth ki umeed hai, jo industry average 17% se thoda kam hai. FDA ne June 2025 mein Bengaluru facilities ko minor compliance issues ke liye 'Voluntary Action Indicated' (VAI) status diya tha, jise address kiya ja raha hai. Analysts ka 'Buy' rating aur target price ₹618.75 hai.
Biocon: Global scaling ke saath financial restructuring
Biocon ki Q3FY26 operating revenue 9% year-on-year badhkar ₹4,173 crore rahi. Yeh growth mainly biosimilars aur generics units se aayi, jise CRDMO business mein hui kami ne balance kiya. Company ne net loss report kiya hai. Biocon R&D aur global manufacturing mein invest kar rahi hai, jo Biopharma SHAKTI initiative ke liye aligned hai. Woh Biocon Biologics ko merge karne ki planning mein hain taaki ek single platform ban sake. January 2026 mein S&P Global Ratings ne Biocon Biologics ki rating ko 'BB+' upgrade kiya, kyunki equity issuance se debt kam hua aur Viatris ke preference shares settle hue. Stock pichhle saal 18% gira hai. Iski market cap lagbhag ₹56,000 crore hai aur P/E ratio 89.75 ke aas-paas hai. Analysts ne isko 'Moderate Buy' kaha hai, with average 12-month price target ₹435.00.
Divi’s Laboratories: Manufacturing backbone, par valuation premium hai
Divi’s Laboratories Active Pharmaceutical Ingredients (APIs), intermediates, aur nutraceuticals mein ek major player hai, jo apni strong custom synthesis services ke liye jaani jaati hai. Q3 mein consolidated income 12.3% badhi, aur profit after tax bhi accha raha. Revenue ka 57% custom synthesis se aata hai, jis se Divi's global companies ke liye ek important manufacturing partner ban gayi hai. Company peptides aur GLP-1 related products ke liye capacity badha rahi hai, jahan commercial volumes 2027 ke end tak expect hai. Backward integration se operational efficiency badhti hai. Divi's financial situation mazboot hai, debt almost zero hai, aur ROCE 20.4% aur ROE 15.4% jaise high returns dikha rahi hai. Lagbhag 89% sales export se aati hai, mainly Europe aur US ko. Yeh operational strength iske premium valuation ko support karti hai, P/E ratio ~64 hai aur market capitalization ₹1.61 lakh crore se zyada hai. Analysts ka 'Hold' consensus hai, average price target ₹6,600.67 hai, jo high valuation ke karan caution dikhata hai.
Market ka view: Alag-alag strategies, alag-alag perception
Biopharma SHAKTI initiative ke national goal ke bawajood, investors Syngene, Biocon, aur Divi's ko bahut alag tarah se dekh rahe hain. Syngene ko client-specific issues ke karan short-term growth challenges face karne pad rahe hain (stock pichhle saal -41.9% gira hai). Biocon mein product-driven growth hai lekin profitability aur financial restructuring abhi bhi challenges hain (stock pichhle saal 13% upar hai aur P/E ratio high hai). Divi's Laboratories custom synthesis aur strong regulatory record ke saath stable, high-margin business dikha rahi hai, jo iske premium valuation (P/E ~64) ko justify karta hai. Global biologics CDMO market 2035 tak 13.3% annually grow hone ki ummeed hai, aur India iska bada share pakdega.